QuidelOrtho to Sell Testing Unit in $1.5B Deal: Report
QuidelOrtho is planning to divest a testing unit for $1.5 billion, according to a Financial Times report.
QuidelOrtho is moving to shed one of its testing divisions in a deal valued at approximately $1.5 billion, the Financial Times reported, marking a significant strategic shift for the diagnostics company as it looks to streamline its portfolio and sharpen its competitive focus.
The planned divestiture signals that QuidelOrtho's leadership is actively reshaping the business following a turbulent post-pandemic period for diagnostics firms. Companies in the sector that saw explosive demand for COVID-19 testing have since grappled with normalizing revenue and mounting pressure from investors to cut costs and improve margins.
Read more Eli Lilly and BioArctic Team Up in New Research Deal →
A $1.5 billion sale, if completed, would represent a meaningful capital event for QuidelOrtho, potentially enabling the company to pay down debt, return cash to shareholders, or reinvest in higher-growth segments of its diagnostics portfolio. The identity of the prospective buyer and a formal closing timeline were not disclosed in initial reports.
The broader diagnostics industry has seen a wave of consolidation and asset sales as major players recalibrate after pandemic-era windfalls faded faster than anticipated. QuidelOrtho, formed through the 2022 merger of Quidel Corporation and Ortho Clinical Diagnostics, has been navigating the integration of those two businesses while simultaneously managing a post-COVID revenue correction.
Investors and analysts will likely scrutinize what unit is being sold and at what multiple to assess whether management is unlocking fair value or exiting at a discount under financial duress. Continue reading at SeekingAlpha.
